GlassScriptPhysician profile
Karim Rasheed
NPI 1285685875
$6,072.39
in general payments reported to CMS, 2019-2025
29 companies · $82.88 in 2025
The $82.88 reported for 2025 was less than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,182 · 2020: $637 · 2021: $180 · 2022: $414 · 2024: $577 · 2025: $82.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $454 · Travel and Lodging: $206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $454.24 |
| Travel and Lodging | $205.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $2,220.24 | 2019-2024 | Senza |
| Abbott Laboratories | $1,209.41 | 2019-2024 | Eterna |
| Boston Scientific Corporation | $917.30 | 2019-2025 | General - Pain Management |
| Arbor Pharmaceuticals, INC. | $223.33 | 2019-2020 | |
| Medtronic, INC. | $147.90 | 2022 | |
| Amgen INC. | $137.75 | 2019-2022 | |
| Spr Therapeutics, INC | $125.19 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $118.23 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $108.04 | 2020-2024 | Relistor |
| Pfizer INC. | $96.88 | 2020-2024 | |
| Vertex Pharmaceuticals Incorporated | $79.55 | 2024 | |
| Averitas Pharma INC. | $65.96 | 2024 | Qutenza |
| Horizon Therapeutics Plc | $65.58 | 2020 | |
| Globus Medical, INC. | $65.56 | 2025 | Senza |
| Redhill Biopharma INC. | $65.13 | 2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Therapeutics, INC. | $57.80 | 2019-2020 | |
| Allergan, INC. | $52.38 | 2019-2020 | |
| Bioventus LLC | $46.88 | 2022 | |
| Lilly USA, LLC | $46.67 | 2020-2022 | |
| Daiichi Sankyo INC. | $43.70 | 2019 | |
| Medtronic USA, INC. | $40.01 | 2019 | |
| Collegium Pharmaceutical, INC. | $24.83 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $20.45 | 2021 | |
| Biotronik INC. | $19.69 | 2022 | |
| Scilex Pharmaceuticals INC. | $19.58 | 2022 | |
| Mdd US Operations, LLC | $18.22 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.56 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.66 | 2019 | |
| Biodelivery Sciences International, INC. | $10.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karim Rasheed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.